image description

Tag: Albert T. Roy

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in […] Read More

ManyOne ARE Making the Difference

May 1, 2023 Last year, the Lupus Research Alliance launched our ManyOne Can campaign during Lupus Awareness Month to offer opportunities to get involved in our efforts to transform lives of people with lupus. This Lupus Awareness Month, we celebrate the great successes that are already being achieved and exciting ventures coming up that involve […] Read More

Lupus Therapeutics Shifting the Paradigm

The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials. How did we achieve what once seemed unobtainable? We created Lupus Therapeutics (an LRA affiliated organization) and since the program started in 2017, […] Read More

Albert T. Roy, Executive Director Lupus Therapeutics, LLC

I’m writing this blog because the Lupus Research Alliance, and its affiliate, Lupus Therapeutics is determined to drive discovery and development of new treatments for lupus! I am proud to serve as Executive Director of Lupus Therapeutics, which serves as fiscal and administrative agent of the Lupus Clinical Investigators Network (LuCIN), a network of 57 […] Read More